After six years of joint work, the HARMONY Alliance reaped the benefits of building a research infrastructure with the best brains of European blood cancer research. Through a wide variety of collaborative activities, HARMONY has truly demonstrated the power of Big Data to improve the treatment of Hematologic Malignancies (HMs) this year.
In HARMONY research projects, scientists and physicians team up to produce novel insights into the biology of HMs. They run new algorithms and perform analyses on the thousands of anonymized data sets stored in the HARMONY Big Data Platform to detect relevant patterns. The results may be used to identify high-risk patients with greater reliability and to guide treatment choices in the future.
In 2022 our researchers:
Defining a Core Outcome Set (COS) for HMs may improve the interpretation and comparability of clinical trials, especially if the COS addresses the needs of all stakeholders. Therefore, the HARMONY Alliance has developed COS with input from patients, clinicians, industry, and regulators/Health Technology Assessment bodies. The results can form the basis for future improvements in patient management.
The HARMONY Alliance brings together European scientists, physicians, patients, and other stakeholders with expertise in HMs. In addition to biomedical research projects, they are running Health Technology Assessment projects and organizing multi-stakeholder activities.
The HARMONY Big Data Platform facilitates state-of-the-art blood cancer research. Careful procedures ensure the anonymization and quality of the data. In addition, HARMONY data scientists have developed sophisticated methods for data harmonization and analysis. In 2022 we have identified more than 150,000 patient datasets for the HARMONY Big Data Platform and have transferred more than 73,000 datasets into the Platform, view details in our data barometer >
The HARMONY Alliance has been working hard to speed up research on HMs in the past six years. More than 100 organizations from 18 European countries already share our mission to personalize treatments for blood cancer patients.
#BigDataforbloodcancer | Big Data accelerate better and faster treatment for Patients with Hematologic Malignancies
The HARMONY Alliance is a Public-Private Partnership for Big Data in Hematology including over 100 organizations such as European medical associations, hospitals, research institutes, patient organizations, pharmaceutical and IT companies.
The HARMONY Alliance is funded by the Innovative Medicines Initiative (IMI) (now called Innovative Health Initiative, IHI) of the European Commission and is currently running two projects: HARMONY (January 2017-June 2023) and HARMONY PLUS (October 2020-September 2023). In addition to the research projects that exploit the HARMONY Big Data Platform, the HARMONY Alliance is running Delphi surveys to develop core outcome sets for HMs, as well as Health Technology Assessment projects and multi-stakeholder activities.
HARMONY uses Big Data analytics to accelerate the development of more effective treatments for blood cancer patients. Data are stored in the HARMONY Big Data Platform, which has already identified over 150,000 anonymized patient records, making it one of the largest databases of its kind. Leading research teams are currently using this wealth of information to answer critical questions about hematologic malignancies that cannot be addressed with other methods.
Receive the latest news. Click here to subscribe!